Learn about Enterobacter infection diagnosis, including clinical documentation and medical coding for Enterobacterales infection and Enterobacter sepsis. Find information on healthcare best practices for identifying and treating this bacterial infection. This resource helps medical professionals accurately document and code cases of Enterobacter infection for optimal patient care and reimbursement.
Also known as
Enterobacter sepsis
Sepsis caused by Enterobacter bacteria.
Other specified bacterial agents
Infections caused by other specified bacteria, including Enterobacter.
Bacterial infection, unspecified
Generalized bacterial infection where the specific bacteria is not identified.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the infection site specified?
When to use each related code
| Description |
|---|
| Infection caused by Enterobacter bacteria. |
| Infection caused by Klebsiella bacteria. |
| Infection caused by Escherichia coli (E. coli). |
Coding Enterobacter sepsis requires documented organ dysfunction. Unspecified infection may be more appropriate without clear clinical evidence.
Accurate differentiation between Enterobacter species and other Enterobacterales is crucial for proper coding and antibiotic stewardship.
Coding Enterobacter infection requires documentation of the infection site (e.g., urinary tract, respiratory). Missing site detail impacts reimbursement and data accuracy.
Q: What are the most effective empiric antibiotic treatment options for suspected Enterobacterales infection in hospitalized patients, considering increasing resistance patterns?
A: Empiric antibiotic treatment for suspected Enterobacterales infections in hospitalized patients must consider the local resistance patterns and the site of infection. Common initial choices often include piperacillin-tazobactam, cefepime, or a carbapenem (e.g., meropenem, imipenem). However, rising carbapenem resistance necessitates careful consideration. In cases of suspected ESBL-producing organisms, carbapenems remain a preferred option. For documented carbapenem-resistant Enterobacterales (CRE) infections, options are more limited and may include ceftazidime-avibactam, meropenem-vaborbactam, or colistin, depending on susceptibility testing. Explore how rapid diagnostic testing can help guide antibiotic selection and optimize patient outcomes. Consider implementing antimicrobial stewardship programs to track resistance patterns and guide empiric therapy choices.
Q: How do I differentiate between colonization and true infection with Enterobacter species in critically ill patients with multiple comorbidities, specifically regarding respiratory cultures?
A: Differentiating between colonization and infection with Enterobacter species, particularly in respiratory cultures of critically ill patients, requires a multifaceted approach. While the presence of Enterobacter in a respiratory culture can suggest infection, it's crucial to consider the clinical context. Factors such as fever, elevated white blood cell count, new or worsening pulmonary infiltrates on imaging, and worsening oxygenation should be considered in conjunction with culture results. Quantitative cultures can be helpful, with higher colony counts suggesting infection rather than colonization. Serial cultures demonstrating persistent growth of the same organism also increase the likelihood of true infection. Furthermore, clinical signs and symptoms inconsistent with other potential diagnoses strengthen the argument for Enterobacter infection. Learn more about the use of biomarkers like procalcitonin to aid in this differentiation. Consider implementing standardized criteria for diagnosing ventilator-associated pneumonia to ensure consistent management.
Patient presents with signs and symptoms suggestive of Enterobacter infection. Differential diagnosis includes Enterobacterales infection, urinary tract infection, pneumonia, bloodstream infection, and sepsis. Presenting complaints may include fever, chills, elevated white blood cell count, tachycardia, hypotension, and altered mental status. Depending on the site of infection, patients may also exhibit localized symptoms such as dysuria, cough, productive sputum, or abdominal pain. Diagnostic workup includes blood cultures, urine cultures, sputum cultures, or other relevant cultures based on the suspected source of infection. Antibiotic susceptibility testing is crucial for guiding appropriate antibiotic therapy. Empirical antibiotic treatment may be initiated pending culture results, considering local antibiograms and prevalence of multidrug-resistant Enterobacter species. Treatment typically involves intravenous antibiotics such as carbapenems, cephalosporins, or fluoroquinolones, with subsequent adjustment based on susceptibility results. Patient risk factors for Enterobacter infection include recent hospitalization, indwelling medical devices such as catheters or ventilators, compromised immune system, and prolonged antibiotic use. The patient's clinical status, including vital signs, laboratory markers of infection, and response to therapy, will be closely monitored. ICD-10 codes for Enterobacter infections will be assigned based on the specific site and manifestation of the infection (e.g., B96.2 for Enterobacter as the cause of diseases classified elsewhere, A49.8 for other specified sepsis). Appropriate CPT codes will be used for billing purposes, reflecting the evaluation and management services, microbiology testing, and therapeutic interventions provided. Patient education on infection prevention measures will be provided. Follow-up care and further diagnostic testing may be necessary depending on the patient's clinical course.